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The WWOX (WW-domain containing oxidoreductase) is a candidate tumour suppressor gene spanning the same chromosome
region, 16q23, as the second most common fragile site (FS), FRA16D. Deletions detected by comparative genomic hybridisation
(CGH) and loss of heterozygosity at microsatellite markers on chromosome 16q are common in many human cancers including
hepatocellular carcinoma (HCC). The development of human HCC is closely associated with exposure to oncogenic viruses and
chemical carcinogens, agents known to frequently target common FS. We examined the status of WWOX genomic DNA, RNA and
protein in 18 cell lines derived from human HCC and found recurrent alterations of the gene. Loss of DNA copy-number confined to
band 16q23 was detected by CGH in several cell lines. Although homozygous deletions of the WWOX gene were not detected,
WWOX mRNA expression was absent or lower in 60% of cell lines. The occurrence of aberrant WWOX reverse transcription–
PCR products with deletion of exons 6–8 correlated significantly with altered WWOX expression. All of the cell lines showing
mRNA downregulation had a decreased or undetectable level of WWOX protein as demonstrated by Western blotting with
antibody to WWOX. Furthermore, 13 out of the 18 cell lines expressed decreased levels or no WWOX protein when compared
with normal liver. These results show that WWOX gene is frequently altered in HCC and raise the possibility that this gene is
implicated in hepatocarcinogenesis.
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Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide and has a high mortality rate, as many tumours
are asymptomatic until the later stages (Thorgeirsson and
Grisham, 2002). Infection with hepatitis B and C viruses (HBV
and HCV) and exposure to the dietary carcinogen, aflatoxin
account for almost 80% of HCC. The progression to HCC is a
stepwise process evolving over a long period of time through
distinct stages associated with cumulative genetic lesions. Despite
the abundance of recurrent genomic alterations identified over the
past several years, relatively few genes have been found to be
affected by deletion, amplification or mutation in HCC (Thor-
geirsson and Grisham, 2002). The identification of genes that
contribute to the development of HCC thus continues to be critical
to our understanding of molecular mechanisms of hepatocarcino-
genesis and the treatment of liver cancer. Chromosomal transloca-
tions, inversions, deletions, and amplifications contribute to the
pathogenesis of human cancer by affecting the expression of genes
involved in regulating cell growth (Bishop, 1987; Mitelman et al,
1997; Hanahan and Weinberg, 2000). Characterisation of recurrent
chromosome changes in human HCC at the molecular level
resulted in the identification of genes implicated in neoplastic
development. From one region of recurrent deletion on the short
arm of chromosome 8 in HCC, a novel gene, DLC-1, was cloned
and recently shown to operate as a tumour suppressor gene in
different types of solid tumours including HCC (Yuan et al, 2003a;
Zhou et al, 2004). Alterations have been detected in several known
genes, including deletion and downregulation of the tumour
suppressor gene FHIT at 3p, amplification of the EMS1 oncogene
at 11q, and high level amplification of the SMAD5 gene at 5q; these
may be pathologically relevant to HCC and might be useful
markers for early detection and prognosis of the disease (Yuan
et al, 2000, 2003b; Zimonjic et al, 2003). The FHIT, EMS1 and
SMAD5 genes are located at aphidicolin (apc)-inducible common
fragile sites (FSs) FRA3B, FRA11B and FRA5C, respectively. The
role of FSs in cancer did not receive much attention until relatively
recently, when it was discovered that genomic alterations in cancer
cells are frequently the consequence of breakage at FSs. Breakage at
FSs inflicted by chemical and physical carcinogens and oncogenic
viruses could result in chromosome translocations, amplification
of proto-oncogenes or deletion of tumour suppressor genes (Smith
et al, 1998; Huebner and Croce, 2001; Popescu, 2003).
WWOX (WW-domain containing oxidoreductase), a candidate
tumour suppressor gene, spans over 1Mb of DNA at 16q23.3–24.1,
the location of FRA16D, the second most active FS in human
genome (Glover et al, 1984; Bednarek et al, 2000, 2001; Ludes-
Meyers et al, 2003). As shown by many comparative genomic
hybridisation (CGH) and microsatellite analyses of primary and
metastatic human HCC and HCC-derived cell lines, loss of DNA
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scopy-number and LOH on the long arm of chromosome 16 are
recurrent alterations (Thorgeirsson and Grisham, 2002). Using a
panel of microsatellite markers the minimal region of LOH in HCC
was defined at 16q23.1–24.1 in one study and localised to intron 8
of the WWOX gene in another (Balsara et al, 2001; Yakicier et al,
2001). Chromosomal regions that are frequently deleted in cancer
are thought to be the loci of tumour suppressor genes, whose loss
or inactivation allows unrestricted cell proliferation. Given the
high frequency of LOH and loss of DNA copy-number on 16q23–
24 in human HCC regardless of their geographic derivation or
association with different etiological factors, we sought to find out
whether alterations of the WWOX gene at FRA16D are recurrent in
HCC and to determine their nature and relevance to hepatocarci-
nogenesis.
MATERIALS AND METHODS
HCC cell lines
The HCC cell lines used in this study have been previously
characterised for their cytogenetic constitution and viral profile
(Yuan et al, 2000, 2003b; Zimonjic et al, 2003). The cells were
cultured in DMEM/F12 medium supplemented with 10% foetal
bovine serum and antibiotics. Five cell lines, SK-Hep-1, 7703,
HepG2, Huh-7, HLF and HLE are negative for HBV.
Northern blot analysis
Total RNA was extracted from cell lines and analysed by Northern
blotting as described earlier (Zimonjic et al, 2003). The blot was
hybridised to a 1490-bp WWOX cDNA probe (nt 62–1551 of
GenBank AF211943), synthesised by RT–PCR using the forward
primer (50-GAGTTCCTGAGCGAGTGGAC-30 located on exon 1)
and the reverse primer (50-CCCCAGGAATTCCCTGCTT-30 located
on exon 9). The gel-purified probe was labelled with [a-
32P]dCTP,
and hybridisation and washing of the blots were performed as
previously described (Zimonjic et al, 2003). The blot was exposed
to autoradiographic film (Kodak, Rochester, NY, USA) for 2 days,
the autoradiogram was scanned on an HP Scanjet 4400c (Hewlett
Packard, Palo Alto, CA, USA). The WWOX probe was stripped
from the blot and the membrane was re-hybridised with the
human b-actin cDNA control probe.
Reverse transcription–PCR analysis
First-strand cDNA was prepared from 5mg of total RNA using the
Superscript first strand synthesis system (Invitrogen, Carsbad, CA,
USA). After reverse transcription, the cDNA was used as a template
for PCR amplification of the human WWOX cDNA. The PCR
mixture contained 2ml of the first-strand reaction, 100mM dNTPs,
1.5mM MgCl2, 1/10 volume of 10  PCR buffer and 10pmol each
of the forward and reverse primers indicated above and 1.25U
AmpliTaq Gold DNA polymerase (Perkin-Elmer, Foster city, CA,
USA). Amplification was carried out as follows: an initial
denaturation for 5min at 951C followed by 35 cycles of 941C for
1min, 571C for 1min, 721C for 1min 30s, and a terminal extension
for 10min at 721C, yielding a 1490-bp product. As a control,
human b-actin was amplified using the forward primer (50-
GTGGGGCGCCCCAGGCACCA-30) and the reverse primer (50-
CTCCTTAATGTCACGCACGATTTC-30). The PCR products were
analysed by gel electrophoresis on 2% agarose gels, stained with
20mgml
 1 of ethidium bromide, and visualised by UV transillu-
mination.
Southern blot analysis
Genomic DNA was extracted from the HCC cell lines by a
modification of the original method (Laird et al, 1991), and normal
human genomic DNA was purchased from Promega (Madison, WI,
USA). In total, 5mg aliquots of each genomic DNA were digested
with the restriction endonuclease EcoRI (New England Biolabs,
Beverly, MA, USA) for 4h and were electrophoresed on a 1%
agarose gel in 1 TAE. Gels were transferred onto Hybond Nþ
membranes (Amersham Pharmacia, Piscataway, NJ, USA) and
were UV crosslinked and hybridised with the
32P-labelled WWOX
cDNA probe, as described above. After washing, the membranes
were exposed overnight to autoradiographic film (Kodak, Roche-
ster, NY, USA) at  801C. Relative intensities of the bands were
normalised using the b-actin cDNA probe as an internal reference
control.
Western blot analyses
Total cell protein lysates were made using RIPA buffer (50mM Tris
pH 7.5, 150mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100,
0.1% SDS) containing protease inhibitor cocktail (Roche, Man-
nheim, Germany). HCCs were washed twice with PBS and then
lysed in RIPA buffer at 41C for 1h, centrifuged at 10000g for
10min to remove cell debris. Human normal liver protein extracts
were prepared from pulverised frozen tissue. In addition, normal
liver protein extract was purchased from ProSci Inc (Poway, CA,
USA). For Western blotting, 50mg of total protein was separated by
12.5% SDS–PAGE and transferred onto PVDF membranes
(Millipore, Billerica, MA, USA). Each gel had a lane containing a
protein lysate from a cell line stably transfected with a WWOX
expression vector (Peo/WWOX) as a reference for standardisation
of independent experiments (Ludes-Meyers et al, 2003). Immuno-
detection was performed using Protein Detectort (KPL, Gaithers-
burg, MD, USA) Western blotting reagents as described by the
manufacturer. WWOX protein was detected using affinity purified
anti-WWOX polyclonal primary antibodies (Ludes-Meyers et al,
2003) and HRP conjugated anti-rabbit secondary antibody (KPL,
1:5000) followed by chemiluminescence autoradiography. Actin
was detected using monoclonal anti-actin antibody (ICN biome-
dicals, Burlingame, CA, USA, 1:1000) and HRP conjugated anti-
mouse secondary antibody (KPL, 1:5000). Quantitation of
Western blots was performed using a Kodak digital science Image
Station 440CF. For each autoradiograph the WWOX values were
first normalised to actin (WWOX/actin) and then standardised to
the WWOX reference. The standardised WWOX/actin for each
HCC was then divided by the standardised WWOX/actin value of
normal liver to obtain HCC WWOX/Normal WWOX.
WWOX immunohistochemistry
Tissue sections from five normal liver samples and five HCC were
stained with WWOX antibody. Prior to anti-WWOX immunostain-
ing, endogenous peroxidase activity was blocked with 3% H2O2 in
water for 10min. Heat-induced epitope retrieval was performed
with 1.0mM EDTA buffer pH 8.0 for 10min in a microwave oven
followed by a 20-min cooldown. In order to block nonspecific
antibody binding, tissue sections were incubated with 10% goat
serum in PBS for 30min. Primary polyclonal rabbit WWOX
antibody (140mgml
 1) was used at a 1:50 dilution overnight at
41C. This was followed by incubation with Envision HRP labelled
polymer conjugated to goat-anti-rabbit immoglobulins (Dako) for
30min at room temperature. Staining development was performed
with DAB with timed monitoring using a positive control sample.
The slides were then counterstained with haematoxylin, dehy-
drated, cleared and mounted.
Mutation screening of the WWOX gene
Genomic DNA isolated from the HCC cell lines was used to amplify
all exons of the WWOX gene. PCR amplifications were performed
using the primers described earlier (Bednarek et al, 2000). The
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sreactions contained 50ng of genomic DNA, 100mM dNTPs, 1.5mM
MgCl2, 1/10 volume of 10  PCR buffer, 10pmol of each primer,
and 1.0U Taq DNA polymerase (Promega, Madison, WI, USA), in
a final volume of 20ml. The PCR conditions and the SSCP analysis
of the products were performed as described earlier (Park et al,
2003).
RESULTS
Comparative genomic hybridisation profile of
chromosome 16
Consistent with CGH analyses of many primary tumours and
metastatic HCC, our CGH profile of HCC cell lines showed
recurrent loss of DNA copy-number on chromosome 16q
(Zimonjic et al, 1999). Furthermore, in the PLC/PRF/5, SK-Hep-
1, HLF, HLE, and SNU387 cell lines, loss of DNA copy-number was
confined to a single band, 16q24, corresponding to the location of
the WWOX gene. In the Hep40 cell line the whole chromosome 16
was over-represented and in HepG2 gain on the long arm was
detected. A representative profile of chromosome 16 in HLE and
HepG2 cells, showing loss at 16q24 and gain of 16q, respectively, is
presented in Figure 1.
Transcriptional expression of WWOX gene
The expression of WWOX mRNA in HCC cell lines was examined
by Northern blotting. The 2.2-kb WWOX mRNA transcript was
detected in normal human liver, but a decreased level or absence of
WWOX expression was observed in 11 out of 18 HCC cell lines. In
SK-Hep-1, 7703, HLF and HLE cells, WWOX mRNA was
undetectable and in Huh6, Chang, Hep3B, Focus, SNU423
SNU475, and SNU387 cells, WWOX was significantly under-
expressed. Only one cell line, HepG2, showed an elevated level of
the WWOX transcript (Figure 2). The cell lines were also examined
by RT–PCR, and the expected product of 1490-bp, spanning exons
1–9 of the WWOX gene, was observed in 15 cell lines and in
normal liver tissue. In 7703 cells, two shorter transcripts were
detected and sequencing revealed that the shortest PCR product
was the WWOX D6–8 isoform (Bednarek et al, 2001; Paige et al,
2001; Driouch et al, 2002) lacking exons 6–8 (Figure 3A and B). The
larger PCR product lacked exons 6–8 but also contained a 96-bp
sequence inserted between exons 5 and 9, identifying a new WWOX
transcript variant (Figure 3C). The insert sequence is encoded by
nts. 5281331–5281425 (NCBI MapViewer build 34 version 2) of
chromosome 16 located within WWOX intron 8. There are no
translational termination codons in the inserted sequence, and
since the WWOX translational reading frame is maintained, the
transcript can potentially encode an approximately 30kDa protein.
The PLC/PRF/5 cell line also showed smaller amplification products
in addition to the normal 1490-bp PCR product. Sequence analysis
of the shorter bands revealed that they displayed the same
alterations, deletion of exons 6–8 with 96-bp insertion and deletion
of exons 6–8 alone, as in the 7703 cell line (not shown).
Expression of WWOX protein
To determine whether WWOX protein expression was altered in
HCC, we performed Western blot analysis of lysates from the HCC
cell lines and from normal liver tissue. We detected WWOX using
affinity purified polyclonal antibody raised against WWOX amino-
acid residues 12–94, containing both of the WW domains. This
antibody has been used to detect WWOX protein expression in
several breast cancer cell lines, demonstrating that altered WWOX
gene expression correlated with altered WWOX protein levels
(Ludes-Meyers et al, 2003). Each normal liver sample had an easily
detectable 46kDa protein band corresponding to WWOX
(Figure 4A). Western analysis revealed that WWOX protein levels
in HCCs varied dramatically compared to normal liver (Figure 4A)
and, with the exception of Hep40 and Hep3B, WWOX mRNA levels
correlated with WWOX protein levels. All of the HCCs had 450%
reduction of WWOX levels compared to normal liver when
normalised to actin (Figure 4B). The majority of cell lines, 72% (13
out of 18), had WWOX expression levels lower than 90% that of
normal liver.
WWOX expression in normal liver tissue was also confirmed by
immunohistochemistry. Hepatocytes from five normal liver
displayed a strong cytoplasmic staining for WWOX protein as
shown in Figure 5A. Of five primary HCC cases analysed by
immunohistochemistry, two of the HCC samples stained very
weakly or moderately for WWOX while one sample was negative
for WWOX staining as shown in Figure 5B and C, respectively.
Figure 1 Comparative genomic hybridisation profile for chromosome
16 in HLE (A) and HepG2 (B) HCC cell lines. HLE cells exhibit loss of
DNA copy-number at region 16q23 (red) and HepG2 cells have gain of
DNA copy-number at two sites on the long arm of chromosome 16
(green).
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Figure 2 Northern blot analysis of total RNA from HCC cell lines. The WWOX cDNA probe detected a 2.2-kb transcript. No signal was detected in the
SK-Hep-1, 7703, HLF and HLE cell lines. The blots were re-hybridised to a b-actin probe as a control for RNA loading.
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To determine the incidence of somatic mutations of WWOX in
HCC, PCR-SSCP analysis of all exons was performed in the 18 HCC
cell lines. Direct sequencing of the bands showing mobility shifts
revealed that they were due to four previously described nucleotide
alterations in the WWOX coding region. The first variation
involved a G to A transition at nucleotide 547 that results in an
aspartic acid to asparagine substitution at amino acid 183 (GAC to
AAC) in 7703 and Focus cell lines. A G to A transition at nucleotide
535, which has been detected previously as frequent polymorph-
ism, was found in amino acid 179 (GCA to ACA) in HepG2 and
Hep40, resulting in an alanine to threonine variation. The third
variation was detected in SNU387, a C to G transversion at
nucleotide 754 that replaced proline with alanine in amino acid 252
(CCT to GCT). The fourth variation was observed in PLC/PRF/5 at
nucleotide 941 and consisted of a G to A transition that caused a
change from arginine to histidine at amino acid 314 (CGC to CAC).
None of these changes affect critical residues of the WW domains
or the SDR domain making it unlikely that they alter WWOX
protein function and very likely they represent common poly-
morphisms rather than somatic mutations.
Concurrent WWOX and FHIT aberrant expression in HCC
In some of the HCC lines examined here, downregulation and lack
of expression of the FHIT tumour suppressor gene spanning the
common FS FRA3B were previously observed (Yuan et al, 2000).
Interestingly, three of the HCC cell lines that did not express
WWOX (SK-Hep-1, 7703, and HLF) also lacked expression of FHIT
(Yuan et al, 2000) (Table 1).
DISCUSSION
In this study we have demonstrated that alteration of WWOX gene
expression is common in cell lines derived from human HCC,
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Figure 3 RT–PCR analysis of full-length open reading frame of the WWOX cDNA and detection of aberrant transcripts in HCC cell lines. (A) PCR
amplification of HCC cell line cDNAs. The 1490-bp product representing the complete open reading frame of the wild-type WWOX transcript was seen in
15 HCC cell lines, whereas only the aberrant transcripts A and B were seen in the 7703 cell line. The PLC/PRF/5 cell line showed the two smaller
amplification products in addition to normal PCR product (1490bp). The amplification of b-actin was shown as a positive control for cDNA synthesis. (B)
Sequence analysis of the two aberrant WWOX transcripts in the 7703 and PLC/PRF/5 cell lines. Fragment A lacked exons 6–8 and contained an intronic
DNA insertion of 96bp. In fragment B, exons 6–8 were deleted. Arrow indicates abnormal fusion between exon 5 and exon 9. (C) DNA sequence of the
newly identified WWOX splice variant. The partial sequence of WWOX exons 5 and 9 is shown and the 96-bp insertion is underlined. The predicted 32
amino-acid sequence of the novel WWOX variant is given, showing the in-frame fusion with the sequence encoded by the insertion (underlined).
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Figure 4 Western blot analysis of WWOX protein in HCCs. (A)
WWOX polyclonal antibody was used to detect WWOX protein in total
protein extracts. Two normal liver samples (normal 1 and normal 2) were
used to determine WWOX levels in nonmalignant tissue. Protein loading
was normalised by Western analysis of actin levels using a mouse antiactin
antibody. (B) Densitometric measurements from Western blots were used
to calculate WWOX protein levels in HCC cell lines relative to WWOX
protein levels in normal liver (WWOX HCC/WWOX normal).
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ssuggesting that WWOX might be involved in hepatocarcinogen-
esis. The interest in the WWOX gene is due to its chromosomal
location and potential tumour suppressor activity (Ludes-Meyers
et al, 2003). The WWOX gene encompasses FRA16D, the second
most actively expressed FS in humans and a region prone to
breakage with an increased risk for carcinogen-induced damage
(Popescu, 2003; Ludes-Meyers et al, 2003). Susceptibility of
FRA16D to carcinogen-induced damage may explain the high
frequency of WWOX gene alterations in HCC, a cancer closely
associated with exposure to chemical carcinogens and infection
with oncogenic viruses (Thorgeirsson and Grisham, 2002).
The data presented here provide evidence for downregulation or
absence of WWOX mRNA expression in 61% of the HCC cell lines
and a low or undetectable level of WWOX protein in 75% of them.
One exception was the HepG2 cell line, expressing the highest level
of WWOX and exhibiting an increased DNA copy number on the
long arm of chromosome 16 (Figure 1).
In general, our results are in contrast to those of Watanabe
et al (2003), who concluded that WWOX was expressed in 47 out
of 48 cancer cell lines analysed, including the HCC cell lines
HLE and HLF, which clearly do not express WWOX RNA and
protein by our analysis. Furthermore, in agreement with our
results and in contrast to those of Watanabe et al (2003), and
supporting a putative tumour suppressor function for WWOX, loss
of expression at RNA and protein level has been clearly
demonstrated in breast, ovarian carcinoma cell lines and in
various haematologic malignancies by several research groups
(Bednarek et al, 2000; Paige et al, 2001; Ludes-Meyers et al, 2003;
Ishii et al, 2003).
Downregulation or absence of WWOX mRNA expression in
various types of cancer can be attributed to mutation, homozygous
deletion, chromosomal translocations within or near the WWOX
locus, hypermethylation of the promoter region or alterations in
transcriptional control (Paige et al, 2001; Ludes-Meyers et al, 2003;
Ishii et al, 2003). Hemizygous loss could also be of relevance since
it could lead to haploinsufficiency, and this abnormality by itself
could be of relevance in cancer development. Most of the HCC cell
lines carry unbalanced translocations of chromosome 16, with
some breakpoints in the vicinity of the WWOX locus, as shown by
G-banding and chromosome painting and ongoing spectral
karyotyping (Keck et al, 1999). Homozygous deletions of WWOX
were not detected by Southern blot hybridisation and nearly all the
cell lines examined have at least one intact chromosome 16q (not
shown). An internal deletion in 7703 cells may be responsible for
the shorter transcripts, but their origin in PLC/PRF/5 cells is not
known. Although the under-representation of the 16q23 region
detected by CGH suggests allelic loss of WWOX, such an alteration
would not be sufficient to explain the low levels of WWOX gene
expression (Driouch et al, 2002). Mutation and deletion in the
coding region of WWOX are rather infrequent in various types of
cancer including HCC (Yakicier et al, 2001). As transcriptional
silencing or downregulation of WWOX was found to be associated
with aberrant DNA methylation and histone acetylation in two
Figure 5 Immunohistochemical detection of WWOX protein in normal
liver and HCC. Representative immunostaining results of WWOX protein
expression. (A) Normal liver tissue sample. Note the strong WWOX
cytoplasmic staining of hepatocytes contrasting with the negative staining of
the stromal components (lower left corner). (B) HCC tissue sample
demonstrating very weak WWOX staining. (C) HCC sample negative for
WWOX staining.
Table 1 Expression of WWOX and FHIT gene in 10 HCC cell lines
Cell line WWOX FHIT
PLC/PRF/5 + +
Focus +  
HepG2 + +
Hep3B +  
Hep40 + +
HLE   +
HLF   
7703   
SK-Hep-1   
Huh7 +  
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lines expressing a very low level of WWOX mRNA after combined
treatment with 5-aza-20-deoxycytidine, inhibitor of DNA methyl-
transferase and trichostatin A, a histone deacetylase inhibitor.
Consistent with previous results in breast tumour cell lines, the
combined treatment did not increase the level of WWOX mRNA
expression (not shown), suggesting that hypermethylation of the
WWOX gene promoter might not be common in HCC (Bednarek
et al, 2001). The low levels of WWOX protein in the majority of the
cell lines could also be due to post-transcriptional regulation. The
Western blot results were further supported by preliminary
immunostaining observations. All normal liver tissue samples
stained strongly for WWOX protein while some HCC samples
displayed weak or undetectable WWOX immunostaining
(Figure 5). Further investigations should be directed toward a
better understanding of the transcriptional and translational
control of WWOX gene expression.
An important observation is the association of WWOX and
FHIT alterations in a number of HCC cell lines. A similar
association of WWOX and FHIT alterations has been reported in
haematopoietic tumours (Ishii et al, 2003). Also, the expression
analysis of 45 common apc-induced FSs in 20 karyotypically
normal individuals showed that only FRA3B and FRA16D were
expressed in all individuals (Denison et al, 2003). It has been
known for some time that FSs replicate late during the cell cycle,
but only more recently the critical role of replication in the
expression of FSs has been demonstrated (Laird et al, 1987). The
replication pattern of FRA3B and FRA16D sequences strongly
suggested that late replication or delayed replication progression is
a determinant factor in FSs expression (Le Beau et al, 1998;
Palakodeti et al, 2004). A model has been proposed in which
spontaneous breaks in ATR-deficient cells represent single-
stranded lesions of unreplicated DNA sequences in G2 resulting
from stalled forks that escape ATR-controlled G2/M checkpoint
(Casper et al, 2002; Arlt et al, 2003). ATR as well as BRCA1 are key
checkpoint genes implicated in genome stability (Casper et al,
2002; Turner et al, 2002). This raises the possibility that breast
tumours derived from patients with BRCA1 mutation might have a
higher rate of WWOX alterations. As common FSs are susceptible
to and preferentially targeted by the same carcinogenic agents, it is
conceivable that breakage at WWOX/FRA16D and FHIT/FRA3B
loci can be inflicted concordantly. Current results with HCC
strongly support the notion that alterations of genes spanning FSs
are the consequence of carcinogen exposure (Croce et al, 1999;
Kuroki et al, 2002). Alterations of the FHIT gene occur early in
tumour development, particularly in cancers related to environ-
mental carcinogens, raising the possibility that carcinogen-
induced alterations of WWOX gene are also an early event in the
process of hepatocarcinogenesis (Yendamuri et al, 2003). WWOX
alterations are common in squamous cell carcinoma of the lung
and oesophageal cancer, both of which are related to tobacco
smoke and alcohol consumption (Kuroki et al, 2002; Yendamuri
et al, 2003). Homozygous deletions at FRA16D have been
identified in HCC derived from patients exposed to aflatoxin B1
(Yakicier et al, 2001). Interestingly, the 7703 HCC cell line that
lacks WWOX protein expression and expresses only aberrant
WWOX transcripts was established from a patient in Qidong,
China, where viral infection and dietary aflatoxin exposure of the
local population are major cooperating risk factors in the
development of HCC (Ming et al, 2002). HBV infection may not
be a contributing factor in loss of WWOX expression, as five of six
HBV-negative HCC cell lines expressed a low level of WWOX
mRNA and protein. Recently, a functional interaction between p73
and WWOX protein resulting in redistribution of nuclear p73 to
the cytoplasm and the suppression of p73 transcriptional activity
was demonstrated (Aqeilan et al, 2004). Understanding the
interations and pathways involved in the tumour suppressor
function of WWOX may provide new targets for therapy of various
cancers including HCC.
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